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Available online 11 February 2016The Genea022 human embryonic stem cell line was derived from a donated, fully commercially consented ART
blastocyst, through ICM outgrowth on inactivated feeders. The line showed pluripotent cell morphology and ge-
nomic analysis veriﬁed a 46, XY karyotype andmale allele pattern through CGH and STR analysis. Pluripotency of
Genea022 was demonstrated with 84% of cells expressed Nanog, 98% Oct4, 55% Tra1–60 and 97% SSEA4, gave a
Pluritest Pluripotency score of 42.95, Novelty of 1.23, demonstrated Alkaline Phosphatase activity and tri-lineage
teratoma formation. The cell line was negative for Mycoplasma and visible contamination.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Resource tableName of stem cell line Genea022 (Alternate ID: SIVF022)Kstitution Genea Biocells
Seerson who created resource Alexis Bosman
Pontact person and email biljana.dumevska@geneabiocells.comate archived/stock date December, 2005
Drigin Human Embryos
Stype of resource Derived human embryonic stem cell lineub-type Human pluripotent cell line
Siey marker expression Nanog, Oct4, Tra1-60, and SSEA4uthentication Identity and purity of cell line conﬁrmed
(Figs. 1-2 and Tables 1-3 below)nk to related literature
(direct URL links and full
references)(Laurent et al., 2010)
http://www.ncbi.nlm.nih.gov/pubmed/
?term=20038950
(Laurent et al., 2011)
http://www.ncbi.nlm.nih.gov/pubmed/
?term=21211785
(McQuade & Balachandran, 2014)
http://www.ncbi.nlm.nih.gov/pubmed/25316320
(Bosman et al., 2015)
http://www.ncbi.nlm.nih.gov/pubmed/25645121formation in public
databasesUK Stem Cell Bank registered, UKSCB: SCS14-60
SNP Data Gene Expression Omnibus accession
numbers, GEO: GSM638433, GEO: GSM638434. This is an open access article underResource detailsthDate of derivatione CC BY-NC-ND licenseDecember 2004aryotype 46, XY — no abnormalities
x Male
luripotent YES — by Nanog, Oct4, Tra1-60, and SSEA4 staining,
Pluritest and Alkaline Phosphatase
isease status Unaffected
erility The cell line is tested and found negative for Mycoplasma
and any visible contamination
bling lines available YES — Genea021 (XY, TS21 affected — UKSCB: SCSC14-60),
Genea023 (XY, UKSCB: SCSC14-60)Materials and methods
Cell line derivation
The zona pellucida of a fresh, blastocyst stage embryo was removed
with a small blade. The embryowasbisected andplated ontoMitomycin
C inactivated human feeders (Detroit 551 HFF - 130,000/well in 4-well)
in 20% KSR medium with (Amit et al., 2000) with 50 ng/mL FGF added
fresh. CGH karyotyping and STR proﬁling were performed at the ﬁrst
cryobanking step from ICMoutgrowthsmaintained on feeders. Alkaline
Phosphatase staining and teratoma formation was performed from
feeders. Cells were then enzymatically passaged as single cells in M2
pluripotent cell maintenance medium (Genea Biocells) and CGH/
karyotyping repeated, immunoﬂuorescent pluripotent marker staining,
Pluritest and sterility testing performed.(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.Morphology and karyotype of Genea022. A) Alkaline Phosphatase activity (passage
14) on human inactivated feeders. B) Karyotypic analysis (passage 38) showing 46, XY
normal, male karyotype.
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1. Karyotyping: Passage 38; for enrichment of metaphase cells, cellular
outgrowths were incubated with either 0.22 ng/mL colcemid
(Invitrogen) and 37.5 g/mL BrdU (Sigma) for 17–19 h or 5 ng/mL
colcemid for 2.5 h. Single cells were subsequently obtained using
Non-Enzymatic Cell Dissociation Solution (Sigma) and transferred
to Sydney IVF's (now Genea) diagnostic cytogenetics laboratory
for preparation of metaphase spreads and cytogenetic analysis by
G-banding. A minimum of 15 metaphase cells were examined, of
which a full karyotype or chromosome count was performed for 5
and 10 of the metaphases respectively.
2. Comparative Genomic Hybridisation (CGH) based chromosomal
analysis: Passage 10; CGH was used to screen targeted regions of
the genome for gains and losses associated with chromosomal
imbalances such as aneuploidy, deletions and duplications. CGH
was performed using SurePrint G3 microarrays (8 × 60 K format)
which were scanned with the Agilent Scanner C and analysedTable 1
CGH analysis summary; Genea022 (passage 10, 4 enzymatic) reporting a male cell line
and no abnormalities detected.
CGH summary
Sample name Genea022p10_TE4
Date reported 8th October 2012
Hybridisation
balance
Balanced hybridization was observed for all chromosomes,
relative to reference DNA
Copy number change No copy number changes above 400 kb were detected
Interpretation Male cell line — no abnormalities detected
Table 2
STR proﬁle; Genea022 (passage 8) demonstrating male allele pattern.
D8S1179 D21S11 D7S820 CSF1PO D3S1358 TH01 D13S317
SIVF022p8 12, 13 28, 29 10, 13 11, 13 15 6 12using Genomic Workbench Standard Edition 5.0 software (Agilent
Technologies).
3. DNA Proﬁling: Passage 8; DNA ‘ﬁngerprinting’ was performed using
the AmpFLSTR Identiﬁler PCR Ampliﬁcation Kit (Applied Biosystems
#4322288) to provide permanent genetic identiﬁcation of the
cell lines. https://www.thermoﬁsher.com/order/catalog/product/
4322288
4. Siblingship testing: Due to the de-identifying of embryos the
siblingship of Genea021, Genea022 and Genea023 was tested at
DNA Labs (a subsidiary of Sydney IVF; Sydney, Australia) via analysis
15 highly variable loci, 15 variable Y chromosome loci andmitochon-
drial DNA sequences in the D-loop HVRI and HVRII regions.
Pluripotency assessment
1. Immunoﬂuorescence: Passage 8 (6 on feeders, 2 enzymatic);
cells were ﬁxed with formalin and stained with Nanog #560483
1:200; Oct4 #560217 1:150: Tra1-60 #560121 1:150; SSEA4
#560308 1:200 (all BD Pharmingen). Images were acquired with
an IN Cell Analyser 6000 and quantiﬁed using In Cell Developer
Software (GE).
2. Pluritest: Passage 9 (6 on feeders, 3 enzymatic); RNA was collected
and subjected to a Pluritest, a bioinformatic assay of pluripotency in
human cells based on gene expression proﬁles (Müller et al., 2012)
3. Alkaline Phosphatase: Passage 14; Genea022 grown on feeders were
stained as per manufacturer's protocol using the Merck Millipore Al-
kaline Phosphatase Detection Kit (SCR004)
4. Teratoma formation: Passage 64; stem cells were received one day
prior to injection. On the day of injection cells were harvested by
manual scraping, washed and resuspended in DMEM/20%KSR for in-
tramuscular injection of cells into the left inner thigh muscle of the
hind leg. Approximately 1–2 × 106 cells (1xT25) in 50 uL were
injected per mouse at one site only. Resultant teratomas were ex-
cised, ﬁxed, sectioned and stained for assessment of tissues from
each of the embryonic germ layers.
Sterility testing
1. Mycoplasma: Passage 36; testing was performed at the Victorian In-
fectious Diseases Reference Laboratory using Mycoplasma Genus
PCR.
2. Microbial contamination: testingwas performed in conjunctionwith
our QC measures. Cells were thawed and cultured in 7 mL antibiotic
free medium (Genea Biocells M2 medium) for 2–3 days at 37 °C. A
clear solution at ~48–72 h indicated lack of bacterial, fungal or
yeast contamination. Clarity of the solution was assessed by Cell Pro-
duction Team.
Veriﬁcation and authentication
Ethics/consents
Karyotyped embryo cells were fully consented for the development
of stem cells by all responsible people through an informed consent pro-
cess (signed de-identiﬁed consent form can be provided upon request).
Donors have received no payment of other beneﬁts for their donation.
Donated embryos originally created by assisted reproduction technolo-
gy (ART) for the purpose of procreation. Embryos were identiﬁed as
unsuitable for implantation, biopsy or freezing due to abnormal devel-
opment. Embryonic outgrowths were developed for consented clinicalD16S539 D2S1338 D19S433 vWA TPOX D18S51 D5S818 FGA
10, 13 17, 18 13, 14 15, 19 8, 11 14, 16 11 20, 22
Table 3
Summary of siblingship testing; de-identiﬁed Genea021, Genea022 and Genea023 share
identical maternal and paternal lines and with variable loci analysis are likely related as
full siblings.
Result
Variable locus analysis SIVF021 and SIVF022 — full sibs inconclusive
SIVF021 and SIVF023 — full sibs practically proven
SIVF022 and SIVF023 — full sibs inconclusive
Y chromosome comparison No mismatches between the lines thus common
paternal lineage
Mitochondrial DNA analysis Identical mitochondrial sequences thus common
maternal line
Interpretation It is likely that all cell lines are related
Fig. 2. Pluripotency validation of Genea022. A) Immunoﬂuorescent staining (10×) of pluripoten
enzymatic). B) Quantitation of expression of pluripotent markers. C) Pluritest pluripotency (le
D) Tri-lineage teratoma formation (passage 24) with gut, squamous and immature mesenchym
474 B. Dumevska et al. / Stem Cell Research 16 (2016) 472–475investigation studies. Results of the studies have been reported back to
the patient.
Morphology
The derived stem cell line, Genea022, morphologically displays ad-
herent monolayer of compact cells in well-deﬁned colonies with high
nuclear to cytoplasmic ratio and prominent nucleoli (Fig. 1A).
Genetic analysis
The cell line has been karyotyped (Fig. 1B, Supplementary Fig. 1) and
tested by CGH (Table 1, Supplementary Fig. 2), which demonstrated 46,
XY karyotype, consistent with original derivation. Analysis of STR
markers showed allele pattern consistent with male genotype
(Table 2, Supplementary Fig. 3). Siblingship analysis showedt cellmarkers SSEA4 (green), Nanog (red), Oct3/4 (green) and Tra1/60 (red), (passage 8, 2
ft) and novelty (right) scores with Genea022 (passage 9, 3 enzymatic) outlined in black.
e.
475B. Dumevska et al. / Stem Cell Research 16 (2016) 472–475Genea021 to be siblingswith Genea022 andGenea023 (Table 3, Supple-
mentary Fig. 4).
Disease Status
Unaffected.
Pluripotency
GENEA022 is pluripotent by;
1. Alkaline Phosphatase stain positivity (Fig. 1A)
2. Immunoﬂuorescence with 84% Nanog positive, 98% Oct4, 55% Tra1-
60 and 97% SSEA4 positive (Fig. 2A, quantiﬁed in 2B).
3. Pluritest with a Pluripotency score of 42.95 and Novelty score of 1.23
(Fig. 2C).
4. Teratoma formation which contained tissues derived from each of
the embryonic germ layers: endoderm, mesoderm, and ectoderm
(Fig. 2D).
Sterility
The cell line is tested and found negative for Mycoplasma and any
visible contamination (Supplementary Fig. 5).
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2016.02.011.References
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